Outcome of Canine Multicentric Lymphoma after Single or Divided Treatment with Cyclophosphamide in Multidrug Chemotherapy
Journal
Topics in Companion Animal Medicine
Journal Volume
41
Date Issued
2020
Author(s)
Abstract
© 2020 Elsevier Inc. Cyclophosphamide is commonly used in combination chemotherapy to treat dogs with lymphoma. The metabolite of cyclophosphamide, acrolein, can irritate urinary bladder and cause sterile hemorrhagic cystitis. Dividing the administration of cyclophosphamide across multiple days may reduce the concentration of this metabolite in urinary bladder and reduce the possibility of cystitis. However, the impact of the therapeutic effect of this modification is not evaluated and compared to traditional single maximum-tolerated dose regimen. Seventy-two dogs with multicentric lymphoma received either bolus doses or divided doses of cyclophosphamide were included in this study. The incidence of hemorrhagic cystitis between 2 cyclophosphamide treatment groups was not significantly different (P = .357). There was no statistical difference in progression-free survival and survival time between 2 groups (P = .267 and P = .346). This modification of cyclophosphamide administration did not reduce the side effect of cystitis or affect remission and survival times in lymphoma dogs.
Subjects
canine | chemotherapy | cyclophosphamide | cystitis | lymphoma
canine; chemotherapy; cyclophosphamide; cystitis; lymphoma
SDGs
Other Subjects
cyclophosphamide; alkylating agent; cyclophosphamide; animal experiment; animal tissue; apoptosis; Article; biochemistry; blood cell count; blood smear; body temperature; body weight; bone marrow biopsy; cancer chemotherapy; Canis; clinical outcome; combination chemotherapy; cyclophosphamide-induced cystitis; dog disease; female; flow cytometry; follow up; gene duplication; histopathology; immunohistochemistry; immunophenotyping; lymphoma; median survival time; multiple cycle treatment; nonhuman; overall survival; progression free survival; prospective study; retrospective study; seasonal variation; survival time; treatment response; urinalysis; animal; bleeding; cystitis; dog; dog disease; drug administration; lymphoma; male; treatment outcome; veterinary medicine; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Dog Diseases; Dogs; Drug Administration Schedule; Female; Hemorrhage; Lymphoma; Male; Retrospective Studies; Treatment Outcome
Publisher
Elsevier {BV}
Type
journal article